“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

04 December 2019
Pharma

Visiongain has launched a new pharma report Liquid Biopsy Market: Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres.

In the past three decades, diagnostic technology has witnessed tremendous advances across all of its branches. Liquid biopsy is a minimally invasive and precise alternative to the surgical biopsies, as it can determine the tumour information through blood samples. This technique allows physicians and surgeons to detect and treat cancer at an early stage.

The lead analyst of the report commented "The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies. Moreover, rising number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities to the key players in the near future."

Leading companies featured in the report include Abbott, Beckman Coulter, Biocept, Inc., Bio-Rad Laboratories, Biotime, Caris Lifesciences, F. Hoffman-La Roche and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever